| 4 min read
Pharma deals, regulatory updates, new treatments and more led the news this week.
| 3 min read
Scientists identified stem cells whose dysregulated calcium signaling drives the degenerative condition, opening the door to novel treatments.
| 4 min read
Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic.News
| 4 min read
A new consortium will characterize 10,000 antibodies to a single standard, aiming to train AI models that flag manufacturing risks before candidates advance.
| 2 min read
In mice, the new drug led to recovery of motor function and vision by protecting nerve fibers and myelin.
| 2 min read
The next-generation tool, called Partita, identified both known and novel genes that contribute to resistance in lymphomas.
| 2 min read
New findings slowed tumor growth in a mouse model of triple-negative breast cancer, offering a new template for RNA drug design.
| 4 min read
A win for autoimmune disease, a set back for Alzheimer’s disease, an FDA backing for a multi-cancer blood test, and more led the news this week.
| 3 min read
Autonomous agents flagged a family of phage enzymes with CRISPR-like repeats, though what the system does remains unknown.
| 4 min read
Proteogenomic analysis of brain tumors identified potential treatment targets and prognostic markers that differed across age, developmental stage, and sex.
| 3 min read
The new highly scalable therapy successfully slowed tumor growth in mouse models of solid tumors.
| 5 min read
From computationally designed repertoires to AI-driven specificity prediction and multispecific therapeutics, antibody researchers are developing new ways to design molecules for the biology they need to influence.
